Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Cancer cell - 1 Jun 2002

Weisberg Ellen, Boulton Christina, Kelly Louise M, Manley Paul, Fabbro Doriano, Meyer Thomas, Gilliland D Gary, Griffin James D

Abstract excerpt

Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML). Here we report the identification of a small molecule FLT3 tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC(50) < 10 nM) by directly inhibiting the tyrosine kinase. Ba/F3-FLT3 cell lines made resistant to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Bone Marrow Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Imatinib Mesylate

Share to Interleukin-3

Share to Piperazines

Share to Protein Kinase C

Share to Staurosporine

Source

Identifiers

PMID: 12124173
DOI: 10.1016/s1535-6108(02)00069-7

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.PMID 12124173Read ↗

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.Semantic proximity Read ↗

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.Semantic proximity Read ↗

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.Semantic proximity Read ↗

Investigational drugs targeting FLT3 for leukemia.Semantic proximity Read ↗

FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).Semantic proximity Read ↗

Targeting FLT3 for the treatment of leukemia.Semantic proximity Read ↗

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read ↗

Novel FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.Semantic proximity Read ↗

The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.